Dr. Hebbar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6530 Troost
Ste A17
Kansas City, MO 64131Phone+1 816-361-0670Fax+1 816-444-6936
Education & Training
- University of ChicagoFellowship, Nephrology, 1993 - 1995
- Hennepin HealthcareResidency, Internal Medicine, 1989 - 1992
- Tulane University School of MedicineClass of 1989
Certifications & Licensure
- MO State Medical License 1995 - 2025
Clinical Trials
- CM4620 Injectable Emulsion Versus Supportive Care in Patients With Acute Pancreatitis and SIRS Start of enrollment: 2018 Mar 12
- A PK/PD Study of CM4620-IE in Patients With Acute Pancreatitis Start of enrollment: 2019 Jan 06
Publications & Presentations
PubMed
- 9 citationsOrai1 calcium channel inhibition prevents progression of chronic pancreatitis.Viktória Szabó, Noémi Csákány-Papp, Marietta Görög, Tamara Madácsy, Árpád Varga
JCI Insight. 2023-07-10 - 17 citationsAuxora vs. placebo for the treatment of patients with severe COVID-19 pneumonia: a randomized-controlled clinical trial.Charles Bruen, Mukhtar Al-Saadi, Edward A Michelson, Maged Tanios, Raul Mendoza-Ayala
Critical Care. 2022-04-08 - 8 citationsAuxora for the Treatment of Patients With Acute Pancreatitis and Accompanying Systemic Inflammatory Response Syndrome: Clinical Development of a Calcium Release-Activa...Charles Bruen, Joseph Miller, John Wilburn, Caleb Mackey, Thomas L Bollen
Pancreas. 2021-04-01
Press Mentions
- CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific MeetingOctober 30th, 2024
- CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora™ in Severe Acute Kidney Injury (AKI)July 9th, 2024
- CalciMedica’s Drug Lowers Mortality Rate in Phase II Covid-19 TrialSeptember 15th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: